Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dose Optimization Study of Idelalisib in Follicular Lymphoma
2015-000366-66Phase 3Unknown
- Sponsor
- Gilead Sciences
- Start
- Sep 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of idelalisib in follicular lymphoma (FL) and non-Hodgkin lymphoma (NHL), sponsored by Gilead Sciences. Primary endpoint: Overall response rate. Status: unknown.
02
Drugs
idelalisib
03
Conditions
follicular lymphoma (FL)non-Hodgkin lymphoma (NHL)
Beyond the preview
Go deeper on 2015-000366-66.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2015-000366-66.